奥氮平与利培酮治疗精神分裂症患者阴性症状临床疗效的对照研究

目的观察研究奥氮平与利培酮对精神分裂症患者阴性症状的疗效和安全性。方法将70例以阴性症状为主的住院精神分裂症患者随机分为奥氮平组（35例）与利培酮组（35例），疗程12周。采用阳性与阴性症状量表（PANSS）及副反应量表（TESS）对照评定疗效和不良反应。结果奥氮平组与利培酮组分别为74．2％、71．4％，差异无显著性（P〉0．05）。两组不良反应发生率分别为37．1％和34．2％，差异无显著性（P〉0．05）。结论奥氮平治疗精神分裂症阴性症状的疗效及安全性总体上与利培酮相当。

The Comparative Study of Olazepine and Risperidone in the Clincal Treatment of Schizophrenia with Predominantly Negative Symptoms

Objective To assess the efficacy and safety of olazepine and risperidone in the treatment of schizophrenia with predominantly negative symptoms. Methods 70 schizophrenia patients with predominantly negative symptoms were randomly assigned to olazepine group （n=35） and risperidone group （n=35） for 12 weeks. The efficacy and side effects were evaluated with positive and negative symptom scale （PANSS） and treatment emergent symptom scales （TESS）. Results There was no significant difference in efficacy between the two groups （74.2% vs 71.4%, P〉0.05）. Both groups had no significant difference in the overall adverse reactions （37.1%, 34.2%, P〉0.05）. Conclusion Olazepine is effective and safe in treatment of negative symptoms of schizophrenia as risperidone.